Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Dysmorphism-cleft palate-loose skin syndrome is a rare, genetic developmental defect during embryogenesis characterized by severe psychomotor delay, intellectual disability, congential, symmetrical circumferential skin creases of arms and legs, cleft palate, and facial dysmorphism (incl. elongated face, high forehead, blepharophimosis, short palpebral fissures, microphthalmia, microcornea, epicanthic folds, telecanthus, microtia, posteriorly angulated ears, broad nasal bridge, microstomia and micrognathia). Additional features reported include short stature, microcephaly, hypotonia, pectus excavatum, severe scoliosis, hypoplastic scrotum, and mixed hearing loss.
Biomarker and diagnostic research for dysmorphism-cleft palate-loose skin syndrome has been reported in the published literature.
Estimated prevalence: Unknown (Unknown prevalence).
No clinical trials have been registered for dysmorphism-cleft palate-loose skin syndrome.
206 publications have been identified in PubMed for dysmorphism-cleft palate-loose skin syndrome. Kisho has analyzed 68 by research type. Research spans Review / Meta-Analysis (53%), Basic Science / Preclinical (29%), and Case Report / Case Series (10%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 36 | 53% |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 11:57 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Laboratory research |
20 |
29% |
Patient case studies | 7 | 10% |
Testing and diagnosis research | 2 | 3% |
Disease patterns and progression | 2 | 3% |
New treatment approaches | 1 | 1% |
Allenbach Y (2026). [PMID: 42127392](https://pubmed.ncbi.nlm.nih.gov/42127392/). *N Engl J Med*. [Review / Meta-Analysis]
Nicholson CL (2026). [PMID: 32644429](https://pubmed.ncbi.nlm.nih.gov/32644429/). *Unknown Journal*. [Basic Science / Preclinical]
Chauffier J (2026). [PMID: 41259063](https://pubmed.ncbi.nlm.nih.gov/41259063/). *JAMA Dermatol*. [Review / Meta-Analysis]
Snowden J (2026). [PMID: 28722942](https://pubmed.ncbi.nlm.nih.gov/28722942/). *Unknown Journal*. [Basic Science / Preclinical]
Di Girolamo D (2025). [PMID: 39340489](https://pubmed.ncbi.nlm.nih.gov/39340489/). *J Invest Dermatol*. [Review / Meta-Analysis]
Jachiet V (2025). [PMID: 40476413](https://pubmed.ncbi.nlm.nih.gov/40476413/). *Rev Prat*. [Review / Meta-Analysis]
Greene CL (2025). [PMID: 39708391](https://pubmed.ncbi.nlm.nih.gov/39708391/). *Mol Genet Metab*. [Review / Meta-Analysis]
Al Ojaimi M (2025). [PMID: 40301961](https://pubmed.ncbi.nlm.nih.gov/40301961/). *Hum Genomics*. [Review / Meta-Analysis]
Spiteri J (2025). [PMID: 40869025](https://pubmed.ncbi.nlm.nih.gov/40869025/). *Int J Mol Sci*. [Review / Meta-Analysis]
Paller AS (2025). [PMID: 40184496](https://pubmed.ncbi.nlm.nih.gov/40184496/). *Br J Dermatol*. [Review / Meta-Analysis]